Short answer
Prime Medicine, Inc. (PRME) filed its Q3 2025 10-Q quarterly report on Nov 7, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $1M (up 486.1% year over year) with net income of −$51M.
Q3 2025 key financials · XBRL
- Revenue
- $1M
- +486.1% YoY · +9.9% QoQ
- Net income
- −$51M
- +3.7% YoY · +3.8% QoQ
- Operating margin
- -4406.0%
- EPS (diluted)
- −$0.30
- +31.8% YoY · +26.8% QoQ
Source: XBRL data from the Prime Medicine, Inc. (PRME) Q3 2025 10-Q on SEC EDGAR. USD.
Prime Medicine, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk: October 1, 2025 federal shutdown could significantly delay FDA submission reviews and SEC market access
- Government funding risk: Shutdown began after September 30, 2025 continuing-resolution expiration, with duration unknown
- Trade-compliance risk: 2025 BIOSECURE Act amendment could restrict suppliers or collaborators tied to certain Chinese biotechnology companies
- Market risk: September 25, 2025 U.S. proposal for 100% tariffs on brand-name or patented drugs
- Liquidity risk: Financial-market instability could make additional financing more expensive or unavailable
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Prime Medicine, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.